These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 28019083)

  • 1. The long path towards implementation of clinical proteomics: Exemplified based on CKD273.
    Nkuipou-Kenfack E; Zürbig P; Mischak H
    Proteomics Clin Appl; 2017 May; 11(5-6):. PubMed ID: 28019083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary peptide-based classifier CKD273: towards clinical application in chronic kidney disease.
    Pontillo C; Mischak H
    Clin Kidney J; 2017 Apr; 10(2):192-201. PubMed ID: 28694965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of the CKD273 peptide classifier in predicting chronic kidney disease progression.
    Critselis E; Lambers Heerspink H
    Nephrol Dial Transplant; 2016 Feb; 31(2):249-54. PubMed ID: 25791724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CKD273, a new proteomics classifier assessing CKD and its prognosis.
    Argilés Á; Siwy J; Duranton F; Gayrard N; Dakna M; Lundin U; Osaba L; Delles C; Mourad G; Weinberger KM; Mischak H
    PLoS One; 2013; 8(5):e62837. PubMed ID: 23690958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to get proteomics to the clinic? Issues in clinical proteomics, exemplified by CE-MS.
    Mischak H
    Proteomics Clin Appl; 2012 Oct; 6(9-10):437-42. PubMed ID: 22821927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Advances in Urinary Peptide and Proteomic Biomarkers in Chronic Kidney Disease: A Systematic Review.
    Catanese L; Siwy J; Mischak H; Wendt R; Beige J; Rupprecht H
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation of CE-MS-identified proteome-based biomarker panels in drug development and patient management.
    Stepczynska A; Schanstra JP; Mischak H
    Bioanalysis; 2016; 8(5):439-55. PubMed ID: 26891752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary proteomics based on capillary electrophoresis-coupled mass spectrometry in kidney disease: discovery and validation of biomarkers, and clinical application.
    Mischak H; Delles C; Klein J; Schanstra JP
    Adv Chronic Kidney Dis; 2010 Nov; 17(6):493-506. PubMed ID: 21044772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomic and metabolomic approaches in the search for biomarkers in chronic kidney disease.
    Cañadas-Garre M; Anderson K; McGoldrick J; Maxwell AP; McKnight AJ
    J Proteomics; 2019 Feb; 193():93-122. PubMed ID: 30292816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary proteomics using capillary electrophoresis coupled to mass spectrometry for diagnosis and prognosis in kidney diseases.
    Magalhães P; Mischak H; Zürbig P
    Curr Opin Nephrol Hypertens; 2016 Nov; 25(6):494-501. PubMed ID: 27584928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CE-MS-based proteomics in biomarker discovery and clinical application.
    Pontillo C; Filip S; Borràs DM; Mullen W; Vlahou A; Mischak H
    Proteomics Clin Appl; 2015 Apr; 9(3-4):322-34. PubMed ID: 25641774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applying proteomics to detect early signs of chronic kidney disease: where has the magic gone?
    Klein JB
    Expert Rev Proteomics; 2017 May; 14(5):387-390. PubMed ID: 28363249
    [No Abstract]   [Full Text] [Related]  

  • 13. Value of Urine Peptides in Assessing Kidney and Cardiovascular Disease.
    Latosinska A; Siwy J; Faguer S; Beige J; Mischak H; Schanstra JP
    Proteomics Clin Appl; 2021 Jan; 15(1):e2000027. PubMed ID: 32710812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Body fluid peptide and protein signatures in diabetic kidney diseases.
    Jankowski J; Schanstra JP; Mischak H
    Nephrol Dial Transplant; 2015 Aug; 30 Suppl 4():iv43-53. PubMed ID: 26209737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomics and personalized medicine: a focus on kidney disease.
    Siwy J; Mischak H; Zürbig P
    Expert Rev Proteomics; 2019 Sep; 16(9):773-782. PubMed ID: 31441341
    [No Abstract]   [Full Text] [Related]  

  • 16. Urinary proteomics and molecular determinants of chronic kidney disease: possible link to proteases.
    Filip S; Pontillo C; Peter Schanstra J; Vlahou A; Mischak H; Klein J
    Expert Rev Proteomics; 2014 Oct; 11(5):535-48. PubMed ID: 24957818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding glomerular diseases through proteomics.
    Mavrogeorgis E; Mischak H; Beige J; Latosinska A; Siwy J
    Expert Rev Proteomics; 2021 Feb; 18(2):137-157. PubMed ID: 33779448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urine proteomics in clinical applications: technologies, principal considerations and clinical implementation.
    Albalat A; Mischak H; Mullen W
    Prilozi; 2011; 32(1):13-44. PubMed ID: 21822176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation of Proteomics in Clinical Trials.
    He T
    Proteomics Clin Appl; 2019 Mar; 13(2):e1800198. PubMed ID: 30702805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary proteomics based on capillary electrophoresis coupled to mass spectrometry in kidney disease.
    Albalat A; Franke J; Gonzalez J; Mischak H; Zürbig P
    Methods Mol Biol; 2013; 919():203-13. PubMed ID: 22976103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.